报价延迟最少15分钟:2025/09/18 02:51 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.563 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.16/--
|
|
企业价值
12.23M
|
| 资产负债 |
|
每股账面净值
0.19
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/18 02:51 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients. |
